New FDA Draft Guidance on Migraine Treatment

The FDA recently released a Draft Guidance on developing new treatments for acute migraine. Of note to those involved in patient-reported outcomes are the sections on endpoint selection which suggests that sponsors examine multiple domains (other than pain itself) as well as the most bothersome symptom to the patient (i.e. nausea). Find the guidance here